Diabetes & Metabolism Journal

Response

Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway (Diabetes Metab J 2024;48:716-29): Shan-Shan Li, Lu Pan, Shipeng Dang, Ru-Xing Wang; Diabetes Metab J. 2024;48(6):1181-1182. Published online November 1, 2024; DOI: https://doi.org/10.4093/dmj.2024.0675

4,019 View
42 Download

PDF PubReader ePub

Original Articles

Metabolic Risk/Epidemiology
Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study: Qing Chang, Yixiao Zhang, Tingjing Zhang, Zuyun Liu, Limin Cao, Qing Zhang, Li Liu, Shaomei Sun, Xing Wang, Ming Zhou, Qiyu Jia, Kun Song, Yang Ding, Yuhong Zhao, Kaijun Niu, Yang Xia; Diabetes Metab J. 2024;48(5):971-982. Published online March 19, 2024; DOI: https://doi.org/10.4093/dmj.2023.0133

12,557 View
262 Download
16 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The incidence density of metabolic dysfunction-associated fatty liver disease (MAFLD) and the effect of a healthy lifestyle on the risk of MAFLD remain unknown. We evaluated the prevalence and incidence density of MAFLD and investigated the association between healthy lifestyle and the risk of MAFLD.
Methods
A cross-sectional analysis was conducted on 37,422 participants to explore the prevalence of MAFLD. A cohort analysis of 18,964 individuals was conducted to identify the incidence of MAFLD, as well as the association between healthy lifestyle and MAFLD. Cox proportional hazards regression was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) with adjustments for confounding factors.
Results
The prevalence of MAFLD, non-alcoholic fatty liver disease, and their comorbidities were 30.38%, 28.09%, and 26.13%, respectively. After approximately 70 thousand person-years of follow-up, the incidence densities of the three conditions were 61.03, 55.49, and 51.64 per 1,000 person-years, respectively. Adherence to an overall healthy lifestyle was associated with a 19% decreased risk of MAFLD (HR, 0.81; 95% CI, 0.72 to 0.92), and the effects were modified by baseline age, sex, and body mass index (BMI). Subgroup analyses revealed that younger participants, men, and those with a lower BMI experienced more significant beneficial effects from healthy lifestyle.
Conclusion
Our results highlight the beneficial effect of adherence to a healthy lifestyle on the prevention of MAFLD. Health management for improving dietary intake, physical activity, and smoking and drinking habits are critical to improving MAFLD.

Citations

Citations to this article as recorded by

The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease
Ioannis Tsomidis, Angeliki Tsakou, Argyro Voumvouraki, Elias Kouroumalis
Biomedicines.2026; 14(1): 151. CrossRef
Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review
Aleksandra Klisic, Ratko Tomašević, Slavko Djuraskovic, Filiz Mercantepe, Ana Ninic
Archives of Medical Science.2026;[Epub] CrossRef
Association between provitamin A carotenoid-rich foods intake and metabolic dysfunction-associated steatotic liver disease risk: mediating effects of socio-economic status and healthy lifestyle
Can Liu, Lin Qu, Xiaoxuan Tang, Yufang Sun, Dianrui Yao, Jingchao Hu, Zaixiang Tang, Jingmin Cheng
British Journal of Nutrition.2026; : 1. CrossRef
Lifestyle mediates the association between normal-weight visceral obesity and MASLD in older adults with hypertension and diabetes
Jun-Yan Xi, Yi-Jing Wang, Xiao-Heng Li, Rui-Qi Ming, Hua-Ling Yan, Xue-Qi Li, Jie Sun, Wei Hu, Jie Hu, Bo Yan, Jian-Jun Bai, Yi-Ning Xiang, Jing Gu, Xiao Lin, Gang Liu, Yuan-Tao Hao
Frontiers in Nutrition.2026;[Epub] CrossRef
Impact of healthy lifestyles on the risk of metabolic dysfunction‐associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle‐aged and elderly cohort in South China
Jun‐Yan Xi, Yi‐Jing Wang, Xiao‐Heng Li, Nuo‐Min Sun, Rui‐Qi Ming, Hua‐Ling Yan, Huan‐Le Cai, Jian‐Jun Bai, Yi‐Ning Xiang, Jing Gu, Xiao Lin, Gang Liu, Yuan‐Tao Hao
Diabetes, Obesity and Metabolism.2025; 27(5): 2800. CrossRef
Cholesteryl ester transfer protein gene variants and metabolic dysfunction-associated steatotic liver disease: genetic associations with steatosis in obese and lean individuals
Asmaa AbdelFattah, Mahmoud Kattab, Hosny Abdel Ghany, Lamiaa Aly, Ahmed Mady, Aly Hamdi, Riham Soliman, Gamal Shiha, Nada El-Domiaty
Egyptian Liver Journal.2025;[Epub] CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study
Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu
Frontiers in Nutrition.2025;[Epub] CrossRef
The relationship between tobacco and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis of observational studies
Jianxiang Jin, Yuping Zhang, Yiping Huang
Frontiers in Medicine.2025;[Epub] CrossRef
Enhancing MAFLD Care: Efficacy of a Multidisciplinary Community Intervention on Self-Management and Hepatic Outcomes
Huan-Jing Cai, Hai-Lun Liang, Lei-Yu Shi, Yi-Hui Rong, Jing Li, Yan Zhang, Rui-Fang Ma
INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2025;[Epub] CrossRef
Mechanistic investigation of DDT/DDE in MASLD/MASH pathogenesis: An integrated network toxicology and transcriptomics approach
Yicheng Jiang, Yuancheng Shao, Jiaming Xue, Zhigang Chen, Qi Liu, Shuai Chen, Xihan Gu, Shufan Zhang, Liming Tang
Ecotoxicology and Environmental Safety.2025; 307: 119390. CrossRef
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
Wenhua Bai, Zheng Zhu
Frontiers in Endocrinology.2025;[Epub] CrossRef
Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease
Tianzhu Chen, Xiang Qin, Jianping Jiang, Beihui He
Frontiers in Nutrition.2024;[Epub] CrossRef
Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease
Tatjana Ábel, Béla Benczúr, Éva Csajbókné Csobod
Frontiers in Medicine.2024;[Epub] CrossRef
Associations of traditional healthy lifestyle and sleep quality with metabolic dysfunction-associated fatty liver disease: two population-based studies
Jialu Yang, Qi Zhang, Wanying Zhao, Bingqi Ye, Siqi Li, Zhuoyu Zhang, Jingmeng Ju, Jialin He, Min Xia, Tiantian Xiong, Yan Liu
Nutrition & Diabetes.2024;[Epub] CrossRef

Basic Research
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway: Shan-Shan Li, Lu Pan, Zhen-Ye Zhang, Meng-Dan Zhou, Xu-Fei Chen, Ling-Ling Qian, Min Dai, Juan Lu, Zhi-Ming Yu, Shipeng Dang, Ru-Xing Wang; Diabetes Metab J. 2024;48(4):716-729. Published online February 27, 2024; DOI: https://doi.org/10.4093/dmj.2023.0031

12,698 View
345 Download
24 Web of Science
27 Crossref

Abstract PDF PubReader ePub

Background
Diabetes-induced cardiac fibrosis is one of the main mechanisms of diabetic cardiomyopathy. As a common histone methyltransferase, enhancer of zeste homolog 2 (EZH2) has been implicated in fibrosis progression in multiple organs. However, the mechanism of EZH2 in diabetic myocardial fibrosis has not been clarified.
Methods
In the current study, rat and mouse diabetic model were established, the left ventricular function of rat and mouse were evaluated by echocardiography and the fibrosis of rat ventricle was evaluated by Masson staining. Primary rat ventricular fibroblasts were cultured and stimulated with high glucose (HG) in vitro. The expression of histone H3 lysine 27 (H3K27) trimethylation, EZH2, and myocardial fibrosis proteins were assayed.
Results
In STZ-induced diabetic ventricular tissues and HG-induced primary ventricular fibroblasts in vitro, H3K27 trimethylation was increased and the phosphorylation of EZH2 was reduced. Inhibition of EZH2 with GSK126 suppressed the activation, differentiation, and migration of cardiac fibroblasts as well as the overexpression of the fibrotic proteins induced by HG. Mechanical study demonstrated that HG reduced phosphorylation of EZH2 on Thr311 by inactivating AMP-activated protein kinase (AMPK), which transcriptionally inhibited peroxisome proliferator-activated receptor γ (PPAR-γ) expression to promote the fibroblasts activation and differentiation.
Conclusion
Our data revealed an AMPK/EZH2/PPAR-γ signal pathway is involved in HG-induced cardiac fibrosis.

Citations

Citations to this article as recorded by

Salidroside attenuates myocardial fibrosis through hindering oxidative stress and inflammation via SIRT1/EZH2 signaling pathway
Wenxue Jin, Xiulan Qiao
Molecular & Cellular Toxicology.2026; 22(4): 661. CrossRef
Sympathetic-like-integrated engineered heart tissue models AGEs-induced adverse remodeling
Yu-hong Wang, Xi-ming Zhu, Xiang Long, Shuo-ji Zhu, Ting-ting Liu, Moussa Ide Nasser, Zi-ming Liao, Jia-cheng Shi, Shu-ting Zhang, Jia-lin Liao, David T. W. Lui, Ping Zhu, Bin Yao, Hai-xia Guan
Cardiovascular Diabetology.2026;[Epub] CrossRef
Epigenetic Regulation and Molecular Mechanisms in Cardiovascular Diseases: A Review of Recent Advances and Therapeutic Implications
Ewelina Młynarska, Kinga Bojdo, Anna Bulicz, Katarzyna Hossa, Wiktoria Lisińska, Paulina Stasiak, Jacek Rysz, Beata Franczyk
International Journal of Molecular Sciences.2026; 27(2): 983. CrossRef
Aerobic Exercise Stabilizes HIF1α through P4HA1 to Activate Nrf2/GPX4 Inhibiting Ferroptosis and Attenuating Diabetic Cardiomyopathy
Sicong Xie, Mingjun Wang, Chenshuo Yu, Fei Zhou, Yu Zheng, Ning Zhang, Yushan Chen, Weihan Kong, Wenzhe Si, Jiaxuan Xu, Yang Zhang, Lei Wang
Diabetes & Metabolism Journal.2026;[Epub] CrossRef
Cannabidiol and diabetic heart disease: Mechanistic evidence and translational challenges
Afolake Arowolo, Oluyomi Adeyemi, Toluwalope Ajonijebu, Aminu Musa, Hygon Mutavhatsindi, Rabia Johnson, Kenechukwu Obikeze
Biomedicine & Pharmacotherapy.2026; 198: 119354. CrossRef
DENSITOMETRIC STUDY OF THE LEFT VENTRICULAR MYOCARDIUM IN RATS WITH EXPERIMENTAL TYPE 1 AND TYPE 2 DIABETES MELLITUS AND THE ADMINISTRATION OF AMINO ACIDS
M. I. Isachenko
Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії.2026; 26(2): 137. CrossRef
Anti-Obesity Effects and Underlying Mechanisms of Total Polyphenols from Cydonia oblonga Miller (Quince) in High-Fat Diet-Induced Obese Mice
Nulibiya Maihemuti, Yipaerguli Paerhati, Nawaz Khan, Kayisaier Abudurousuli, Dilihuma Dilimulati, Alhar Baishan, Alifeiye Aikebaier, Wenting Zhou
Molecules.2026; 31(15): 2582. CrossRef
Inhibitors of Epigenetic Modulators as Therapeutic Alternatives for Cardiovascular Diseases
Gustavo A. Barraza, Wendy Rosales, Carlos Meléndez
Mini-Reviews in Medicinal Chemistry.2026; 26(11): 803. CrossRef
Mechanisms and therapeutic potential of AMPK signaling pathway in the regulation of lipid metabolism
Xiaohong Gong, Xueling Dai, Xiujun Liu, Jian Zhao, Yaxuan Sun
Molecular Biology Reports.2026;[Epub] CrossRef
Peroxisome proliferator-activated receptor gamma (PPARγ) as a mechano-metabolic transducer: coordinating lipid homeostasis through mechanical cues
Ming-Yue Zhong, Shu-Ya Yang, Wen-Hui Xu, Ying-Kang Zhang, Jun Zhao
Molecular Biomedicine.2026;[Epub] CrossRef
Xiaoyao San restores NK cell anti-fibrotic activity through regulation of EZH2 in liver fibrosis
Qingqing Chen, Jia Wang, Dong Guo, Fang Kou, Hong Cai, Guangyong Zheng, Yiyu Lu
Phytomedicine.2026; 162: 158818. CrossRef
Enhancer of Zeste Homolog 2 Inhibition Attenuates Atrial Fibrillation Post-Myocardial Infarction Through Reduced Atrial Fibrosis
Tian-Peng Wei, Wen-Rui Wang, Xiao-Lu Zhang, Huan-Huan Liu, Ying Liu, Fan Yang, Xiao-Yu Liu, Ru-Xing Wang, Ling-Ling Qian
Reviews in Cardiovascular Medicine.2026;[Epub] CrossRef
A Computational Approach to Identify Novel Protein Targets Uncovers New Potential Mechanisms of Action of Mirtazapine S(+) and R(−) Enantiomers in Rett Syndrome
Ottavia Maria Roggero, Nicolò Gualandi, Viviana Ciraci, Vittoria Berutto, Emanuele Carosati, Enrico Tongiorgi
Journal of Neurochemistry.2025;[Epub] CrossRef
ER-α36 prevents high glucose-induced cellular senescence and apoptosis in renal tubular cell
Dehai Yu, Ling Luo, Yu Liang, Huili Zhou, Yinghui Xiao, Xingna An, Yingzhao Wang, Zhonggao Xu, Weixia Sun, Wanning Wang
Frontiers in Endocrinology.2025;[Epub] CrossRef
EZH2 in non-cancerous diseases: expanding horizons
Renjing Jin, Jianlin Zhang, Yuqing Wang, Ziyu Chen, Xuan He, Xintong Zhang, Zhen Tan, Celina G Kleer, Ye Li, Deli Wang, Lixiang Xue
Protein & Cell.2025;[Epub] CrossRef
Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights
Chen-Ying Zhu, Pei-Han Yu, Qi Sun, De-Fei Hong, Chang Yang, Hua Naranmandura
Pharmacological Research.2025; 218: 107862. CrossRef
Epigenetics Plays a Role in the Pathogenesis and Treatment of Diabetes
Kajetan Kiełbowski, Estera Bakinowska, Andrzej Pawlik
Genes.2025; 16(7): 769. CrossRef
UM-164 alleviates high starch diet-induced hepatic abnormal lipid accumulation via inhibiting pentose phosphate pathway and mTOR-SREBPs signaling in channel catfish (Ictalurus punctatus)
Qisheng Lu, Xiaochen Ma, Guoli Han, Jinglu Jia, Jingyue Cao, Haokun Liu, Junyan Jin, Zhimin Zhang, Yunxia Yang, Xiaoming Zhu, Shouqi Xie, Dong Han
Aquaculture Reports.2025; 44: 103031. CrossRef
Β-Hydroxybutyrate inhibits centriole duplication and mitochondrial dysfunction through β-hydroxybutyrylation of ANXA11 in diabetic cardiomyopathy rats
Jingyu Liu, Bin Wu, Xin Nian, Shiying Huang, Yaxian Song, Yaxin Guan, Fang Sun, Xiao Meng, Shengting Huang
Cellular Signalling.2025; 136: 112086. CrossRef
The role of AMPK signaling pathway in the pathogenesis of type 2 diabetes mellitus with its complications and related metabolic disorders
Kibur Hunie Tesfa, Chernet Desalegn Gebeyehu, Asrat Tadele Ewunetie, Endalkachew Gugsa, Amare Nigatu Zewdie, Gashaw Dessie, Hiwot Tezera Endale
Metabolism Open.2025; 28: 100397. CrossRef
Metabolic-epigenetic interactions in heart failure: Current understanding and future directions
Benjamin Flowers, Bea Duric
Biochemical and Biophysical Research Communications.2025; 783: 152608. CrossRef
Cardiometabolic Therapies Shape Non-Coding RNA Landscapes in Cardiovascular Fibrosis
Erica Floris, Francesco Nutile, Claudia Cozzolino, Virginia Pontecorvi, Antonella Bordin, Elena De Falco, Vittorio Picchio, Isotta Chimenti, Francesca Pagano
Metabolites.2025; 15(10): 664. CrossRef
Emerging in Diabetic Cardiomyopathy: Molecular Pathways and Targets for Therapeutic Intervention
Mansi Vinodkumar Trivedi, Hemant R. Jadhav, Anil Bhanudas Gaikwad
Drug Development Research.2025;[Epub] CrossRef
An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory
Tongyue Yang, Feng Qi, Feng Guo, Mingwei Shao, Yi Song, Gaofei Ren, Zhao Linlin, Guijun Qin, Yanyan Zhao
Molecular Medicine.2024;[Epub] CrossRef
Farrerol Alleviates Diabetic Cardiomyopathy by Regulating AMPK-Mediated Cardiac Lipid Metabolic Pathways in Type 2 Diabetic Rats
Jia Tu, Qiaoling Liu, Huirong Sun, Luzhen Gan
Cell Biochemistry and Biophysics.2024; 82(3): 2427. CrossRef
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway (Diabetes Metab J 2024;48:716-29)
Shan-Shan Li, Lu Pan, Shipeng Dang, Ru-Xing Wang
Diabetes & Metabolism Journal.2024; 48(6): 1181. CrossRef
Targeting Cardiac Fibrosis in Diabetic Heart Failure: The Role of the EZH2, AMPK, and PPAR-γ Pathways (Diabetes Metab J 2024;48:716-29)
Jooyeop Lee, Joon Ho Moon
Diabetes & Metabolism Journal.2024; 48(6): 1176. CrossRef

First
Prev
Page of 1
Next
Last

Search